John Hohneker
Director/Board Member at CURIS, INC.
Net worth: - $ as of 2024-03-30
Profile
John A.
Hohneker is currently an Independent Director at Curis, Inc., a Director at Trishula Therapeutics, Inc., a Director at Sonata Therapeutics, Inc., and a Director at Carisma Therapeutics, Inc. Previously, he served as the President, Chief Executive Officer & Director at Anokion SA and Kanyos Bio, Inc. He was also an Independent Director at Humanigen, Inc., Dimension Therapeutics, Inc., and Evelo Biosciences, Inc. Additionally, he served as a Director at Cygnal Therapeutics, Inc., Aravive, Inc., BioTheryX, Inc., and Torque Therapeutics, Inc. Prior to these roles, he was the Head of Research & Development at Forma Therapeutics, Inc. and the Senior Vice President & Global Head of Development & Immunology at Novartis AG.
Dr. Hohneker holds a doctorate degree from the University of Medicine & Dentistry of New Jersey and Robert Wood Johnson Medical School, as well as an undergraduate degree from Gettysburg College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CURIS, INC.
-.--% | 2024-03-24 | 0 ( -.--% ) | - $ | 2024-03-30 |
ARAVIVE, INC.
-.--% | 2023-08-02 | 0 ( -.--% ) | - $ | 2023-12-30 |
EVELO BIOSCIENCES, INC.
-.--% | 2023-06-07 | 0 ( -.--% ) | - $ | 2024-03-30 |
| 2024-03-31 | 0 ( -.--% ) | - $ | 2024-03-30 | |
HUMANIGEN INC
-.--% | 2023-04-10 | 0 ( -.--% ) | - $ | 2024-03-30 |
John Hohneker active positions
| Companies | Position | Start |
|---|---|---|
| CURIS, INC. | Director/Board Member | 2021-12-01 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 2024-03-31 |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Director/Board Member | 2020-08-31 |
Sonata Therapeutics, Inc.
 Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | Director/Board Member | - |
Former positions of John Hohneker
| Companies | Position | End |
|---|---|---|
| ARAVIVE, INC. | Director/Board Member | 2024-01-16 |
| HUMANIGEN, INC. | Director/Board Member | 2023-07-17 |
| EVELO BIOSCIENCES, INC. | Director/Board Member | 2023-07-10 |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Chief Executive Officer | 2021-01-31 |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Chief Tech/Sci/R&D Officer | 2017-12-31 |
Training of John Hohneker
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
| Gettysburg College | Undergraduate Degree |
| Robert Wood Johnson Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| CURIS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Health Technology |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | Health Technology |
- Stock Market
- Insiders
- John Hohneker